Welcome to our dedicated page for Aspire Biopharma Holdings SEC filings (Ticker: ASBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspire Biopharma Holdings, Inc. filings document the company’s public-company reporting, securities offerings, shareholder votes, governance matters and capital structure. Proxy materials cover stockholder approval matters involving warrant issuances, warrant adjustments, Nasdaq Rule 5635(d) compliance and reverse stock split authority.
Material-event reports and amendments describe securities purchase agreements, Series A convertible preferred stock, registration rights, financing tranches and corrections to prior disclosures. Registration statement filings provide offering disclosures, risk factors, operating and financial information, and security-structure details for the company’s common stock and related securities.
Aspire Biopharma Holdings, Inc. (ASBP) reported that it plans to distribute an investor presentation on August 19, 2026. The company furnished this presentation as Exhibit 99.1 to provide additional information to the market under a Regulation FD disclosure.
The common stock and public warrants of Aspire Biopharma Holdings, Inc. trade on The Nasdaq Stock Market LLC under the symbols ASBP and ASBPW, respectively. The report was authorized on behalf of the company by Chief Executive Officer Kraig Higginson.
Highbridge Capital Management, LLC filed Amendment No. 1 reporting beneficial ownership of Aspire Biopharma Holdings, Inc. common stock issuable upon exercise of warrants held by its advised funds. Highbridge reports 78 shares of common stock with sole voting and dispositive power, representing 0.0% of the class based on 1,295,234 shares outstanding as of May 13, 2026. The position is held on behalf of certain Highbridge funds, and overall ownership is disclosed as 5 percent or less of the class.
Aspire Biopharma Holdings, Inc. reported minimal commercial activity but a much stronger balance sheet for the quarter and six months ended June 30, 2026. Net revenue was $63,104 for the quarter and $91,457 for the first half of 2026, producing a negative gross margin due to $73,421 of cost of revenue and a $42,372 inventory write-off. The company remains in an early commercialization phase.
The operating loss was $2.68 million for the quarter and $4.32 million year-to-date, but total net loss of $4.49 million for the first half of 2026 improved significantly from $17.92 million a year earlier as prior-period stock-based compensation and financing-related charges rolled off. Cash and cash equivalents increased to $12.17 million from $1.00 million at December 31, 2025, and working capital reached $11.78 million.
Major capital structure changes included issuance of 26,250 shares of Series A Convertible Preferred Stock in February and April 2026, of which 17,050 remained outstanding at June 30, 2026, and multiple conversions of debt and preferred stock into common shares, increasing common shares outstanding to 1,295,234 after two reverse stock splits. Total liabilities fell to $1.78 million from $7.69 million, turning a $(6.38) million stockholders’ deficit into positive equity of $11.76 million. Management states existing liquidity is sufficient to fund operations for at least one year after issuance of these statements.
Aspire Biopharma Holdings, Inc. shareholder Gary Shirinyan reported his ownership of the company’s common stock. He beneficially owns 99,900 shares of common stock, representing 7.7% of the outstanding class. He has sole voting power and sole dispositive power over all 99,900 shares, with no shared voting or dispositive authority.
Aspire Biopharma Holdings, Inc. completed the acquisition of Dura Driver Control Systems (DCS), purchasing 100% of DCS’s shares for approximately $30.0 million in cash. DCS, a tier-one automotive systems supplier, becomes a wholly owned subsidiary and is expected to enhance Aspire’s revenue, earnings and cash flow profile.
DCS generated unaudited revenue of $209.5 million and Adjusted EBITDA of $22.3 million in 2025, and revenue of $103.9 million and Adjusted EBITDA of $10.5 million for the six months ended June 30, 2026. Aspire entered into a $22.5 million senior secured revolving credit facility to help fund the acquisition alongside cash on hand.
The board also approved and the company issued convertible promissory notes with an aggregate principal of $3,750,000, sold for $3,000,000 (a 20% original issue discount), intended for working capital and future growth opportunities. These notes are convertible into common stock at a $8.00 per-share conversion price and were issued in a private offering relying on Section 4(a)(2) and Rule 506(b) exemptions.
Lance Friedman reports beneficial ownership of common stock of Aspire Biopharma Holdings, Inc. on an amended Schedule 13G. He is a United States citizen and lists 25 N Market Street, Suite 205, Jacksonville, Florida as his address. Friedman reports beneficial ownership of 107,323 shares of common stock, representing 7.92% of the class, with sole voting and sole dispositive power over all 107,323 shares and no shared power. The holdings include 107,323 shares of common stock with a floor price of $7.92 per share. He also holds preferred stock that is convertible into common stock but subject to a 9.99% ownership blocker, which prohibits conversion if it would cause his ownership to exceed 9.99% of Aspire Biopharma’s outstanding common stock.
Aspire Biopharma Holdings, Inc. clarified the current terms of its Nasdaq-listed public warrants, which trade under the symbol ASBPW, following requests from warrant holders. The warrants were originally issued on February 23, 2022 in connection with the initial public offering of its predecessor, Power Up Acquisition Corp.
The warrants initially had an exercise price of $11.50 per share, subject to adjustment for events such as share consolidations. After a 1-for-30 reverse stock split on January 16, 2026 and an additional 40-for-1 reverse split on May 11, 2026, each public warrant now carries an exercise price of $13,800 per share and a ratio of 1,200 warrants to purchase one share of common stock.
Aspire Biopharma Holdings, Inc. reports a Schedule 13G filing showing Alois Ryan Rubenbauer III beneficially owns 65,000 shares of Common Stock. The filing states this equals 5.0% of the class based on 1,295,234 shares outstanding as of the quarter ended March 31, 2026. The cover page shows sole voting and dispositive power over 65,000 shares.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on June 16, 2026, where stockholders constituting a quorum voted on several matters. The filing shows that each proposal received strong support, with the first proposal receiving 1,742,683 votes for, 107,523 against, and 4,818 abstentions, and no broker non-votes. Two additional proposals also passed with similar levels of support, including one with 1,745,709 votes for and another with 1,739,702 votes for, and no broker non-votes in any case. The company remains listed on The Nasdaq Stock Market LLC under the symbols ASBP for its common stock and ASBPW for its warrants.
Aspire Biopharma Holdings, Inc. reported that its shareholder meeting held on June 9, 2026 was adjourned because a quorum was not reached. The company has rescheduled the meeting to June 16, 2026 at 10:00 a.m. EST. The online access link remains www.colonialstock.com/AspireBiopharma2026.